megaflopp/iStock via Getty Images
Our diversified allocation to the broad healthcare spectrum continues to yield positive alpha in the back end of FY22. One standout is our buy thesis on Sanara MedTech Inc. (NASDAQ:SMTI) that's rallied 19.5% to the upside from our
Analyst’s Disclosure:I/we have a beneficial long position in the shares of SMTI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
